Q1 EPS Estimates for Bausch + Lomb Cut by HC Wainwright

Bausch + Lomb Co. (NYSE:BLCO) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for Bausch + Lomb in a research report issued on Friday, February 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.15 per share for the quarter, down from their prior estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.18 EPS and Q4 2025 earnings at $0.20 EPS.

Several other analysts have also weighed in on the stock. Morgan Stanley lowered shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a research note on Monday, December 2nd. Stifel Nicolaus lowered their target price on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, January 29th. Bank of America lowered their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, January 16th. Finally, Royal Bank of Canada lowered their target price on Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.83.

Bausch + Lomb Stock Up 1.4 %

Shares of Bausch + Lomb stock opened at $16.04 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The firm has a market cap of $5.65 billion, a P/E ratio of -17.62, a P/E/G ratio of 0.85 and a beta of 0.46. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The business has a 50-day moving average price of $17.25 and a 200 day moving average price of $18.17.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. Bausch + Lomb’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.24 earnings per share.

Hedge Funds Weigh In On Bausch + Lomb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLCO. Alberta Investment Management Corp grew its holdings in Bausch + Lomb by 36.0% in the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock worth $54,328,000 after buying an additional 796,400 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in Bausch + Lomb in the 4th quarter valued at about $14,122,000. King Street Capital Management L.P. bought a new position in Bausch + Lomb in the 3rd quarter valued at about $14,122,000. Arrowstreet Capital Limited Partnership grew its position in Bausch + Lomb by 51.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock valued at $21,996,000 after buying an additional 414,138 shares in the last quarter. Finally, Barclays PLC bought a new position in Bausch + Lomb in the 3rd quarter valued at about $5,797,000. 11.07% of the stock is owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.